ClinicalTrials.gg

Program

cizutamig

Also written as “Cizutamig” and “EMB-06”.

Its studies are mostly in Myasthenia Gravis · Lupus Erythematosus, Systemic · Milk Hypersensitivity · Multiple Myeloma, led by 2 companies.

Furthest: phase 2, since Sep 23, 20255 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB42 open or runningphase 1since Sep 23, 2025Sep 23, 2025Dec 2027phase 1 · NCT07215650
Shanghai EpimAb Biotherapeutics10 open or runningphase 2since Jan 28, 2021Jan 28, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 28, 2021First study: phase 2 study in RecurrenceNew to Shanghai EpimAb BiotherapeuticsShanghai EpimAb Biotherapeutics · NCT04735575 · 40 enrolled · Australia, China
  2. Sep 23, 2025UCB's first studies: 2 phase 1 studiesNew to UCBUCB · NCT07215663, NCT07215650
  3. Nov 13, 2025Phase 1 study in Healthy Participants StudyUCB · NCT07236411 · 24 enrolled · Australia
  4. Dec 23, 2025Phase 1 study in Hypersensitivity, ImmediateUCB · NCT07408869 · Australia

Ahead

  1. Dec 2027Primary completion: phase 1 study in Myasthenia GravisUCB · NCT07215650
  2. Dec 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicUCB · NCT07215663

TargetBeta

“A tetravalent, bispecific antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07408869Hypersensitivity, Immediate · Australia1WithdrawnUCBDec 20260
NCT07236411Healthy Participants Study · Australia1CompletedUCBApr 16, 202624
NCT07215650Myasthenia Gravis · China1RecruitingUCBDec 202744
NCT07215663Lupus Erythematosus, Systemic · China1RecruitingUCBDec 202747
NCT04735575Recurrence · Australia, China2TerminatedShanghai EpimAb BiotherapeuticsAug 20, 202440

How it is read

Names in the registry

  • “Cizutamig”, 3 entries
  • “cizutamig”, 1 entry
  • “EMB-06”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.